1. Home
  2. OVLY vs LYEL Comparison

OVLY vs LYEL Comparison

Compare OVLY & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oak Valley Bancorp (CA)

OVLY

Oak Valley Bancorp (CA)

HOLD

Current Price

$32.61

Market Cap

283.4M

Sector

Finance

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$12.63

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OVLY
LYEL
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.4M
320.1M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
OVLY
LYEL
Price
$32.61
$12.63
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
29.0K
230.3K
Earning Date
04-22-2026
05-13-2026
Dividend Yield
2.27%
N/A
EPS Growth
N/A
N/A
EPS
0.64
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
$50.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.41
$9.28
52 Week High
$35.97
$45.00

Technical Indicators

Market Signals
Indicator
OVLY
LYEL
Relative Strength Index (RSI) 43.90 41.53
Support Level $32.64 $11.59
Resistance Level $34.05 $14.14
Average True Range (ATR) 0.95 1.19
MACD -0.12 -0.08
Stochastic Oscillator 45.33 4.25

Price Performance

Historical Comparison
OVLY
LYEL

About OVLY Oak Valley Bancorp (CA)

Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: